カテゴリ： Transparency Market Research, 世界, 医療/バイオ

放射性医薬品におけるセラノスティクスの世界市場2023～2031：放射性同位体別

■ 英語タイトル：Radiopharmaceutical Theranostics Market (Radioisotope: Technetium-99, Gallium-68, Iodine-131, Radium-223, Fluorine-18, Yttrium-90, Lutetium-177, Copper-67 & 64, Samarium-153, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

調査会社Transparency Market Research社が発行したリサーチレポート（データ管理コード：TMR23MA071）■ 発行会社/調査会社：Transparency Market Research
■ 商品コード：TMR23MA071
■ 発行日：2023年3月20日
■ 調査対象地域：アメリカ、ヨーロッパ、その他地域
■ 産業分野：医薬品
■ ページ数：226
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧）USD5,795 ⇒換算￥880,840見積依頼/購入/質問フォーム
Multi User（5名様閲覧）USD8,795 ⇒換算￥1,336,840見積依頼/購入/質問フォーム
Corporate License（法人閲覧）USD11,795 ⇒換算￥1,792,840見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Transparency Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[放射性医薬品におけるセラノスティクスの世界市場2023～2031：放射性同位体別]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Transparency Market Research社の当調査レポートでは、世界の放射性医薬品におけるセラノスティクス市場規模が、2023年の30億ドルから2031年に124億ドルとなり、予測期間中に年平均成長率15.1%で拡大すると展望しています。本書は、放射性医薬品におけるセラノスティクスの世界市場にフォーカスし、市場状況や今後の動向などをまとめた資料です。序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要インサイト、放射性同位体別（テクネチウム99、ガリウム68、ヨウ素131、ラジウム223、その他）分析、用途別（腫瘍、心臓病、その他）分析、供給源別（原子炉、サイクロトロン）分析、アプロ―チ別（標的治療薬、コンパニオン診断薬）分析、地域別（アメリカ、ヨーロッパ、その他地域）分析、競争状況など、以下の構成で掲載しています。また、市場参入企業として、Advanced Accelerator Applications (Novartis AG)、Aurobindo Pharma、Bayer AG、Blue Earth Diagnostics (Bracco)、Cardinal Health、Clarity Pharmaceuticals、GE Healthcare、Jubliant Radiopharma、Lantheus Medical Imaging、Navidea Biopharmaceuticals, Inc.、SOFIE、Telix Pharmeceuticalsなどの情報が含まれています。
・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場概要
・主要インサイト
・世界の放射性医薬品におけるセラノスティクス市場規模：放射性同位体別
- テクネチウム99の市場規模
- ガリウム6の市場規模
- ヨウ素131の市場規模
- ラジウム22の市場規模
- その他放射性同位体の市場規模
・世界の放射性医薬品におけるセラノスティクス市場規模：用途別
- 腫瘍における市場規模
- 心臓病における市場規模
- その他における市場規模
・世界の放射性医薬品におけるセラノスティクス市場規模：供給源別
- 原子炉における市場規模
- サイクロトロにおける市場規模
・世界の放射性医薬品におけるセラノスティクス市場規模：アプロ―チ別
- 標的治療薬の市場規模
- コンパニオン診断薬の市場規模
・世界の放射性医薬品におけるセラノスティクス市場規模：地域別
- アメリカの放射性医薬品におけるセラノスティクス市場規模
- ヨーロッパの放射性医薬品におけるセラノスティクス市場規模
- その他地域の放射性医薬品におけるセラノスティクス市場規模
・競争状況

Radiopharmaceutical Theranostics Market – Scope of Report
TMR’s report on the global radiopharmaceutical theranostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global radiopharmaceutical theranostics market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global radiopharmaceutical theranostics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the radiopharmaceutical theranostics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global radiopharmaceutical theranostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global radiopharmaceutical theranostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global radiopharmaceutical theranostics market.

The report delves into the competitive landscape of the global radiopharmaceutical theranostics market. Key players operating in the global radiopharmaceutical theranostics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global radiopharmaceutical theranostics market profiled in this report.

Key Questions Answered in Global Radiopharmaceutical Theranostics Market Report
• What is the sales/revenue generated by radiopharmaceutical theranostics across all regions during the forecast period?
• What are the opportunities in the global radiopharmaceutical theranostics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Radiopharmaceutical Theranostics Market – Research Objectives and Research Approach
The comprehensive report on the global radiopharmaceutical theranostics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global radiopharmaceutical theranostics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global radiopharmaceutical theranostics market.

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Radiopharmaceutical Theranostics Market
4. Market Overview
    4.1. Introduction
        4.1.1. Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, 2017-2031
        4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
    5.1. Regulatory Scenario
    5.2. Key Distribution Strategies
    5.3. Pricing Analysis
    5.4. Patents on Radiotracers
    5.5. Technological Advancements in Radiopharmaceutical Theranostics
    5.6. Radiotracer Type – Overview
    5.7. COVID-19 Pandemic Impact on Industry
6. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Radioisotope
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Radioisotope, 2017-2031
        6.3.1. Technetium-99
        6.3.2. Gallium-68
        6.3.3. Iodine-131
        6.3.4. Radium-223
        6.3.5. Fluorine-18
        6.3.6. Yttrium-90
        6.3.7. Lutetium-177
        6.3.8. Copper-67 & 64
        6.3.9. Samarium-153
        6.3.10. Others
    6.4. Market Attractiveness Analysis, by Radioisotope
7. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Application
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Application, 2017-2031
        7.3.1. Oncology
        7.3.2. Cardiology
        7.3.3. Others
    7.4. Market Attractiveness Analysis, by Application
8. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Source
    8.1. Introduction & Definition
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Source, 2017-2031
        8.3.1. Nuclear Reactors
        8.3.2. Cyclotrons
    8.4. Market Attractiveness Analysis, by Source
9. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Approach
    9.1. Introduction & Definition
    9.2. Key Findings/Developments
    9.3. Market Value Forecast, by Approach, 2017-2031
        9.3.1. Targeted Therapeutic (Rx)
        9.3.2. Companion Diagnostic (DX)
    9.4. Market Attractiveness Analysis, by Approach
10. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Radiotracer Type
    10.1. Introduction & Definition
    10.2. Key Findings/Developments
    10.3. Market Value Forecast, by Radiotracer Type, 2017-2031
        10.3.1. Peptidic
        10.3.2. Non-peptidic
    10.4. Market Attractiveness Analysis, by Radiotracer Type
11. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by End-user
    11.1. Introduction & Definition
    11.2. Key Findings/Developments
    11.3. Market Value Forecast, by End-user, 2017-2031
        11.3.1. Hospitals
        11.3.2. Academic & Research Institutes
        11.3.3. Others
    11.4. Market Attractiveness Analysis, by End-user
12. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Region
    12.1. Key Findings
    12.2. Market Value Forecast, by Region, 2017-2031
        12.2.1. U.S.
        12.2.2. Europe
        12.2.3. Rest of the World
    12.3. Market Attractiveness Analysis, by Region
13. U.S. Radiopharmaceutical Theranostics Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Radioisotope, 2017-2031
        13.2.1. Technetium-99
        13.2.2. Gallium-68
        13.2.3. Iodine-131
        13.2.4. Radium-223
        13.2.5. Fluorine-18
        13.2.6. Yttrium-90
        13.2.7. Lutetium-177
        13.2.8. Copper-67 & 64
        13.2.9. Samarium-153
        13.2.10. Others
    13.3. Market Value Forecast, by Application, 2017-2031
        13.3.1. Oncology
        13.3.2. Cardiology
        13.3.3. Others
    13.4. Market Value Forecast, by Source, 2017-2031
        13.4.1. Nuclear Reactors
        13.4.2. Cyclotrons
    13.5. Market Value Forecast, by Approach, 2017-2031
        13.5.1. Targeted Therapeutic (Rx)
        13.5.2. Companion Diagnostic (DX)
    13.6. Market Value Forecast, by Radiotracer Type, 2017-2031
        13.6.1. Peptidic
        13.6.2. Non-peptidic
    13.7. Market Value Forecast, by End-user, 2017-2031
        13.7.1. Hospitals
        13.7.2. Academic & Research Institutes
        13.7.3. Others
    13.8. Market Attractiveness Analysis
        13.8.1. By Radioisotope
        13.8.2. By Application
        13.8.3. By Source
        13.8.4. By Approach
        13.8.5. By Radiotracer Type
        13.8.6. By End-user
14. Europe Radiopharmaceutical Theranostics Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Radioisotope, 2017-2031
        14.2.1. Technetium-99
        14.2.2. Gallium-68
        14.2.3. Iodine-131
        14.2.4. Radium-223
        14.2.5. Fluorine-18
        14.2.6. Yttrium-90
        14.2.7. Lutetium-177
        14.2.8. Copper-67 & 64
        14.2.9. Samarium-153
        14.2.10. Others
    14.3. Market Value Forecast, by Application, 2017-2031
        14.3.1. Oncology
        14.3.2. Cardiology
        14.3.3. Others
    14.4. Market Value Forecast, by Source, 2017-2031
        14.4.1. Nuclear Reactors
        14.4.2. Cyclotrons
    14.5. Market Value Forecast, by Approach, 2017-2031
        14.5.1. Targeted Therapeutic (Rx)
        14.5.2. Companion Diagnostic (DX)
    14.6. Market Value Forecast, by Radiotracer Type, 2017-2031
        14.6.1. Peptidic
        14.6.2. Non-peptidic
    14.7. Market Value Forecast, by End-user, 2017-2031
        14.7.1. Hospitals
        14.7.2. Academic & Research Institutes
        14.7.3. Others
    14.8. Market Value Forecast, by Country/Sub-region, 2017-2031
        14.8.1. Germany
        14.8.2. U.K.
        14.8.3. France
        14.8.4. Italy
        14.8.5. Spain
        14.8.6. Rest of Europe
    14.9. Market Attractiveness Analysis
        14.9.1. By Radioisotope
        14.9.2. By Application
        14.9.3. By Source
        14.9.4. By Approach
        14.9.5. By Radiotracer Type
        14.9.6. By End-user
        14.9.7. By Country/Sub-region
15. Rest of the World Radiopharmaceutical Theranostics Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Radioisotope, 2017-2031
        15.2.1. Technetium-99
        15.2.2. Gallium-68
        15.2.3. Iodine-131
        15.2.4. Radium-223
        15.2.5. Fluorine-18
        15.2.6. Yttrium-90
        15.2.7. Lutetium-177
        15.2.8. Copper-67 & 64
        15.2.9. Samarium-153
        15.2.10. Others
    15.3. Market Value Forecast, by Application, 2017-2031
        15.3.1. Oncology
        15.3.2. Cardiology
        15.3.3. Others
    15.4. Market Value Forecast, by Source, 2017-2031
        15.4.1. Nuclear Reactors
        15.4.2. Cyclotrons
    15.5. Market Value Forecast, by Approach, 2017-2031
        15.5.1. Targeted Therapeutic (Rx)
        15.5.2. Companion Diagnostic (DX)
    15.6. Market Value Forecast, by Radiotracer Type, 2017-2031
        15.6.1. Peptidic
        15.6.2. Non-peptidic
    15.7. Market Value Forecast, by End-user, 2017-2031
        15.7.1. Hospitals
        15.7.2. Academic & Research Institutes
        15.7.3. Others
    15.8. Market Attractiveness Analysis
        15.8.1. By Radioisotope
        15.8.2. By Application
        15.8.3. By Source
        15.8.4. By Approach
        15.8.5. By Radiotracer Type
        15.8.6. By End-user
16. Competition Landscape
    16.1. Market Player Competition Matrix (by tier and size of companies)
    16.2. Market Share Analysis, by Company (2022)
    16.3. Company Profiles
        16.3.1. Advanced Accelerator Applications (Novartis AG)
            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.1.2. Product Portfolio
            16.3.1.3. Financial Overview
            16.3.1.4. SWOT Analysis
            16.3.1.5. Strategic Overview
        16.3.2. Aurobindo Pharma
            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.2.2. Product Portfolio
            16.3.2.3. Financial Overview
            16.3.2.4. SWOT Analysis
            16.3.2.5. Strategic Overview
        16.3.3. Bayer AG
            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.3.2. Product Portfolio
            16.3.3.3. Financial Overview
            16.3.3.4. SWOT Analysis
            16.3.3.5. Strategic Overview
        16.3.4. Blue Earth Diagnostics (Bracco)
            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.4.2. Product Portfolio
            16.3.4.3. Financial Overview
            16.3.4.4. SWOT Analysis
            16.3.4.5. Strategic Overview
        16.3.5. Cardinal Health
            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.5.2. Product Portfolio
            16.3.5.3. Financial Overview
            16.3.5.4. SWOT Analysis
            16.3.5.5. Strategic Overview
        16.3.6. Clarity Pharmaceuticals
            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.6.2. Product Portfolio
            16.3.6.3. Financial Overview
            16.3.6.4. SWOT Analysis
            16.3.6.5. Strategic Overview
        16.3.7. GE Healthcare
            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.7.2. Product Portfolio
            16.3.7.3. Financial Overview
            16.3.7.4. SWOT Analysis
            16.3.7.5. Strategic Overview
        16.3.8. Jubliant Radiopharma
            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.8.2. Product Portfolio
            16.3.8.3. Financial Overview
            16.3.8.4. SWOT Analysis
            16.3.8.5. Strategic Overview
        16.3.9. Lantheus Medical Imaging
            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.9.2. Product Portfolio
            16.3.9.3. Financial Overview
            16.3.9.4. SWOT Analysis
            16.3.9.5. Strategic Overview
        16.3.10. Navidea Biopharmaceuticals, Inc.
            16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.10.2. Product Portfolio
            16.3.10.3. Financial Overview
            16.3.10.4. SWOT Analysis
            16.3.10.5. Strategic Overview
        16.3.11. SOFIE
            16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.11.2. Product Portfolio
            16.3.11.3. Financial Overview
            16.3.11.4. SWOT Analysis
            16.3.11.5. Strategic Overview
        16.3.12. Telix Pharmaceuticals
            16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.12.2. Product Portfolio
            16.3.12.3. Financial Overview
            16.3.12.4. SWOT Analysis
            16.3.12.5. Strategic Overview

List of Tables

Table 01: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031

Table 02: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 03: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Source, 2017–2031

Table 04: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Approach, 2017–2031

Table 05: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017–2031

Table 06: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 07: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Country/Region, 2017–2031

Table 08: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031

Table 09: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 10: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Source, 2017–2031

Table 11: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Approach, 2017–2031

Table 12: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017–2031

Table 13: U.S. Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 14: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 15: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031

Table 16: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 17: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Source, 2017–2031

Table 18: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Approach, 2017–2031

Table 19: EU Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017–2031

Table 20: EU Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 21: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031

Table 22: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 23: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Source, 2017–2031

Table 24: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Approach, 2017–2031

Table 25: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radiotracer Type, 2017–2031

Table 26: Rest of the World Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 医療用サイクロトロンの世界市場2023～2031：製品別、用途別
  • 超音波内視鏡針の世界市場2023～2031：製品別、用途別
  • 睡眠ポリグラフ装置の世界市場（2022～2031）：製品別、チャンネル別
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(TMR23MA071 )"放射性医薬品におけるセラノスティクスの世界市場2023～2031：放射性同位体別" (英文：Radiopharmaceutical Theranostics Market (Radioisotope: Technetium-99, Gallium-68, Iodine-131, Radium-223, Fluorine-18, Yttrium-90, Lutetium-177, Copper-67 & 64, Samarium-153, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031)はTransparency Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。